Zhengye Biotechnology Holding Limited Class A Ordinary Shares (ZYBT) is a publicly traded Healthcare sector company. As of May 21, 2026, ZYBT trades at $0.88 with a market cap of $43.74M and a P/E ratio of 0.00. ZYBT moved +0.00% today. Year to date, ZYBT is -22.78%; over the trailing twelve months it is -88.54%. Its 52-week range spans $0.68 to $14.30. Rallies surfaces ZYBT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Zhengye Biotechnology Sees 37.6% Revenue Drop to RMB116.4M, RMB83M Loss: Zhengye Biotechnology’s FY2025 revenue fell 37.6% to RMB116.4 million with gross profit margin contracting to 20.5%, resulting in a net loss of RMB83.0 million. The company held RMB50.3 million in cash at year-end and secured approvals for three National Category new veterinary drugs.
| Metric | Value |
|---|---|
| Price | $0.88 |
| Market Cap | $43.74M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $14.30 |
| 52-Week Low | $0.68 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
ZYBT analyst coverage data. Average price target: $0.00.